Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

A Randomized Placebo-Controlled Phase 1 Trial in Healthy Volunteers Investigating the Safety, Pharmacokinetics and Pharmacodynamics of a Novel FLT3/IRAK4 Inhibitor, Lomonitinib (ZE46-0134)

John C. Byrd, Amy Burd, Brian Ledwith, Fraser Pickersgill, Kate Dokukina, Ruben Karapetian, Megan E. Johnstone, Erin K. Hertlein, Ola A. Elgamal, Alexei Pushechnikov, Nikolay Savchuk, Iain Dukes

Blood (2024) 144 (Supplement 1): 1396.

https://doi.org/10.1182/blood-2024-211491

Published: 2024

Journal Articles

Development of ZE66-0205, a Novel MALT1 Degrader for Treatment of B-Cell Malignancies

Sara Elgamal, Casie Furby, Marissa Long, Kaytlynn Fyock, Thomas M. Sesterhenn, Megan E. Johnstone, Jianmin Pan, Shesh N. Rai, Alexander Khvat, Ruben Karapetian, Alexey Ryakhovskiy, Elena Bulanova, Vladislav Parchinsky, Nikolay Savchuk, Iain Dukes, Amy Burd, Erin K. Hertlein, John C. Byrd

Blood (2024) 144 (Supplement 1): 2783.

https://doi.org/10.1182/blood-2024-202696

Published: 2024

Journal Articles

MYD88 Is Mutated in Clonal Hematopoiesis and Drives Altered Immune Cell Populations

Jennifer Yeung, Sophia Philbrook, Kwangmin Choi, Kathleen Hueneman, Erin K. Hertlein, John C. Byrd, Daniel Starczynowski

Blood (2024) 144 (Supplement 1): 2663.

https://doi.org/10.1182/blood-2024-208279

Published: 2024

Journal Articles

The Potent Dihydroorotate Dehydrogenase Inhibitor, Hosu-53, Exhibits Compelling Monotherapy Efficacy in Multiple Myeloma and Augments CD47 Targeted Therapy

Gerard Hilinski, Blaise Stearns, Sandip Vibhute, Tiffany Hughes, Susheela Tridandapani, Megan E. Johnstone, Thomas E. Goodwin, Jeffrey Patrick, Chad E. Bennett, Don Benson, John C. Byrd, Ola A. Elgamal, Erin K. Hertlein

Blood (2023) 142 (Supplement 1): 4692.

https://doi.org/10.1182/blood-2023-189238

Published: 2023

Journal Articles

A Novel Selective BCL2 Inhibitor with Limited Immune Suppression and Improved Safety Compared to Venetoclax

Blood (2023) 142 (Supplement 1): 4153.

https://doi.org/10.1182/blood-2023-189266

Published: 2023

Journal Articles

Genome-Wide Methylome and Transcriptome Profiling of Acute Myeloid Leukemia Derived Bone Marrow Mesenchymal Cells Identify Age Group Specific Biological Pathway Dysregulation in the Bone Marrow Microenvironment of AML

Amina Abdul-Aziz, James R. Lerma, Amy Kovacs, Shesh N. Rai, Jianmin Pan, Liang Niu, Alice Mims, Christopher C. Oakes, John C. Byrd, Erin K. Hertlein

Blood (2023) 142 (Supplement 1): 5620.

https://doi.org/10.1182/blood-2023-189973

Published: 2023

Journal Articles

Therapeutic Targeting of FLT3 Gate Keeper Mutation with E2082-0047 in Traditional and a Novel Immunocompetent Murine Adoptive Transfer Model of AML

Blood (2023) 142 (Supplement 1): 1544.

https://doi.org/10.1182/blood-2023-189259

Published: 2023

Journal Articles

Development of a Fully Immunocompetent Adoptive Transfer In Vivo Model of Npm1 cA ;Idh2 R140Q ;Flt3 ITD AML

Chia Sharpe, Mariah Johnson, Sydney Fobare, Ola A. Elgamal, Bonnie K. Harrington, Allison Mustonen, Kinsey Bryant, Carolyn Cheney, James R. Lerma, Jean Truxall, Casie Furby, Marissa Long, Kaytlynn Fyock, Alan Shih, Ross L Levine, Erin K. Hertlein, John C. Byrd

Blood (2023) 142 (Supplement 1): 1386.

https://doi.org/10.1182/blood-2023-189975

Published: 2023

Journal Articles

Near-Tetraploidy Is Strongly Associated with Development of Richter's Transformation in Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib

Blood (2016) 128 (22): 3198.

https://doi.org/10.1182/blood.V128.22.3198.3198

Published: 2016

Journal Articles

Leukemic Cell Expressed CTLA-4 Suppresses T Cells Via Down-Modulation of CD80 By Trans-Endocytosis

Priscilla Do, BS, Kyle A. Beckwith, PhD, Larry Beaver, Brittany G. Griffin, Xiaokui Mo, PhD MAS, Jeffrey Jones, MD MPH, Erin K. Hertlein, PhD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD

Blood (2016) 128 (22): 3221.

https://doi.org/10.1182/blood.V128.22.3221.3221

Published: 2016

Journal Articles

NFkB p50 ( Nfkb1 ) Contributes to Disease in the Eu-TCL1 Mouse Model of Chronic Lymphocytic Leukemia

Erin K Hertlein, PhD, Timothy L Chen, David M Lucas, PhD, Nikhil Gupta, Jessica MacMurray, Virginia M. Goettl, DVM , PhD, Amy M. Lehman, MAS, Amy J. Johnson, PhD, John C Byrd, MD

Blood (2015) 126 (23): 1248.

https://doi.org/10.1182/blood.V126.23.1248.1248

Published: 2015

Journal Articles

BRAF V600E Induces ABCB1/P-Glycoprotein Expression and Drug Resistance in B-Cells Via AP-1 Activation

Yo-Ting Tsai, MS, Gerard Lozanski, MD, Amy M. Lehman, MAS, Ellen Sass, Erin K. Hertlein, PhD, Santosh Salunke, Ching-Shih Chen, PhD, Michael R. Grever, MD, John C. Byrd, MD, David M. Lucas, PhD

Blood (2015) 126 (23): 2477.

https://doi.org/10.1182/blood.V126.23.2477.2477

Published: 2015

Journal Articles

The Aberrantly Expressed Long Noncoding RNA, TRERNA1, Predicts for Aggressive Disease in Chronic Lymphocytic Leukemia

Cecelia R Miller, MS, Amy S. Ruppert, MAS, Kevin Coombes, PhD, Amy M. Lehman, MAS, James S. Blachly, MD, David M. Lucas, PhD, Michael R. Grever, MD, Martin S Tallman, MD, Ian W. Flinn, MD PhD, Laura Z. Rassenti, PhD, Thomas J. Kipps, MD PhD, Deepa Sampath, PhD, John C Byrd, MD, Erin K. Hertlein, PhD

Blood (2015) 126 (23): 2911.

https://doi.org/10.1182/blood.V126.23.2911.2911

Published: 2015

Journal Articles

Mir-155 Expression Is Associated with Chemoimmunotherapy Outcome and Is Modulated By Bruton’s Tyrosine Kinase Inhibition with Ibrutinib

Daphne Guinn, Amy S. Ruppert, MAS, Kami J. Maddocks, MD, Samantha Jaglowski, MD MPH, Amber L. Gordon, Thomas S. Lin, MD PhD, Richard A. Larson, Guido Marcucci, MD, Erin K Hertlein, PhD, Jennifer A. Woyach, MD, Amy J. Johnson, PhD, John C. Byrd, MD

Blood (2014) 124 (21): 3297.

https://doi.org/10.1182/blood.V124.21.3297.3297

Published: 2014

Journal Articles

OSU-T315, An Integrin-Linked Kinase (ILK) Inhibitor, Induces Apoptosis By Targeting B Cell Receptor and CD49d Mediated AKT/ERK Activation In Chronic Lymphocytic Leukemia Cells

Ta-Ming Liu, YongHua Ling, Mitch A. Phelps, PhD, Jennifer A. Woyach, MD, Erin K Hertlein, PhD, William H. Towns, Jessica MacMurray, Santosh B. Salunke, PhD, Ching-Shih Chen, PhD, John C. Byrd, MD, Amy J. Johnson, PhD

Blood (2013) 122 (21): 2523.

https://doi.org/10.1182/blood.V122.21.2523.2523

Published: 2013

Journal Articles

A Phase I Trial of the Intravenous (IV) Hsp90 Inhibitor 17-DMAG (alvespimycin) in Patients (pts) with Relapsed Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Kami Maddocks, MD, Erin K Hertlein, PhD, Joseph M. Flynn, DO, MPH, Leslie A Andritsos, MD, Amy J. Wagner, Timothy L. Chen, Mitch A. Phelps, PhD, Michael R. Grever, MD, Amy J. Johnson, PhD, John C. Byrd, MD, Jeffrey A. Jones, MD, MPH

Blood (2012) 120 (21): 1800.

https://doi.org/10.1182/blood.V120.21.1800.1800

Published: 2012

Journal Articles

The Hsp90 Inhibitor 17-DMAG Increases SOCS3 and Regulates Cytokine Production, Migration and Cell Death in Chronic Lymphocytic Leukemia

Erin K Hertlein, PhD, Timothy L. Chen, Rainer Claus, MD, Christoph Plass, PhD, Amy Lehman, David Jarjoura, PhD, Kami Maddocks, MD, Jeffrey A. Jones, MD, MPH, David M. Lucas, PhD, Amy J. Johnson, PhD, John C. Byrd, MD

Blood (2012) 120 (21): 1362.

https://doi.org/10.1182/blood.V120.21.1362.1362

Published: 2012

Journal Articles

Protein Arginine Methyltransferase 5 (PRMT5) Over-Expression Is Essential for Epstein-Barr Virus-Driven B-Cell Transformation.

Lapo Alinari, MD., Ph.D., Fengting Yan, M.D., Ph.D., Porsha Smith, John T. Patton, Carl Quinion, Bo Yu, Ph.D, Christian Tyler Earl, Mark E Lustberg, MD, PhD, Lynda Villagomez, Erin K Hertlein, PhD, John C. Byrd, MD, Leona Ayers, MD, Tasneem Motiwala, PhD, Sarmila Majumder, PhD, Chenglong Li, Ph.D., Said Sif, Ph.D., Samson T. Jacob, PhD, Robert A. Baiocchi, M.D., Ph.D.

Blood (2012) 120 (21): 2378.

https://doi.org/10.1182/blood.V120.21.2378.2378

Published: 2012

Journal Articles

The Novel Proteasome Inhibitor Carfilzomib Functions Independently of p53 to Induce Potent Cytotoxicity in Primary Chronic Lymphocytic Leukemia Cells and a Defective NF-κB Response,

Sneha V. Gupta, Erin K Hertlein, PhD, Jennifer A. Woyach, MD, Ellen J. Sass, Melanie E. Davis, John C. Byrd, MD, David M. Lucas, PhD

Blood (2011) 118 (21): 3510.

https://doi.org/10.1182/blood.V118.21.3510.3510

Published: 2011

Journal Articles

Micro-RNA and Gene Expression In CLL: Network Analysis Elucidating the Complex Role of the NF-κB Signaling Pathway In Disease.

Erin K Hertlein, PhD, Lianbo Yu, Jianying Zhang, Amy J. Johnson, PhD, David Lucas, PhD, Guido Marcucci, MD, David Jarjoura, John C. Byrd, MD

Blood (2010) 116 (21): 3642.

https://doi.org/10.1182/blood.V116.21.3642.3642

Published: 2010

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

A Randomized Placebo-Controlled Phase 1 Trial in Healthy Volunteers Investigating the Safety, Pharmacokinetics and Pharmacodynamics of a Novel FLT3/IRAK4 Inhibitor, Lomonitinib (ZE46-0134)

Development of ZE66-0205, a Novel MALT1 Degrader for Treatment of B-Cell Malignancies

MYD88 Is Mutated in Clonal Hematopoiesis and Drives Altered Immune Cell Populations

The Potent Dihydroorotate Dehydrogenase Inhibitor, Hosu-53, Exhibits Compelling Monotherapy Efficacy in Multiple Myeloma and Augments CD47 Targeted Therapy

A Novel Selective BCL2 Inhibitor with Limited Immune Suppression and Improved Safety Compared to Venetoclax

Genome-Wide Methylome and Transcriptome Profiling of Acute Myeloid Leukemia Derived Bone Marrow Mesenchymal Cells Identify Age Group Specific Biological Pathway Dysregulation in the Bone Marrow Microenvironment of AML

Therapeutic Targeting of FLT3 Gate Keeper Mutation with E2082-0047 in Traditional and a Novel Immunocompetent Murine Adoptive Transfer Model of AML

Development of a Fully Immunocompetent Adoptive Transfer In Vivo Model of Npm1 cA ;Idh2 R140Q ;Flt3 ITD AML

Near-Tetraploidy Is Strongly Associated with Development of Richter's Transformation in Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib

Leukemic Cell Expressed CTLA-4 Suppresses T Cells Via Down-Modulation of CD80 By Trans-Endocytosis

NFkB p50 ( Nfkb1 ) Contributes to Disease in the Eu-TCL1 Mouse Model of Chronic Lymphocytic Leukemia

BRAF V600E Induces ABCB1/P-Glycoprotein Expression and Drug Resistance in B-Cells Via AP-1 Activation

The Aberrantly Expressed Long Noncoding RNA, TRERNA1, Predicts for Aggressive Disease in Chronic Lymphocytic Leukemia

Mir-155 Expression Is Associated with Chemoimmunotherapy Outcome and Is Modulated By Bruton’s Tyrosine Kinase Inhibition with Ibrutinib

OSU-T315, An Integrin-Linked Kinase (ILK) Inhibitor, Induces Apoptosis By Targeting B Cell Receptor and CD49d Mediated AKT/ERK Activation In Chronic Lymphocytic Leukemia Cells

A Phase I Trial of the Intravenous (IV) Hsp90 Inhibitor 17-DMAG (alvespimycin) in Patients (pts) with Relapsed Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

The Hsp90 Inhibitor 17-DMAG Increases SOCS3 and Regulates Cytokine Production, Migration and Cell Death in Chronic Lymphocytic Leukemia

Protein Arginine Methyltransferase 5 (PRMT5) Over-Expression Is Essential for Epstein-Barr Virus-Driven B-Cell Transformation.

The Novel Proteasome Inhibitor Carfilzomib Functions Independently of p53 to Induce Potent Cytotoxicity in Primary Chronic Lymphocytic Leukemia Cells and a Defective NF-κB Response,

Micro-RNA and Gene Expression In CLL: Network Analysis Elucidating the Complex Role of the NF-κB Signaling Pathway In Disease.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only